Trial reportAnnals of surgical oncology2026
Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SABER): A Randomized Open-Label Phase 2 Trial.
Trial report in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04986930 (Randomized Phase 2 Study of mFOLFIRINOX With or Without Stereotactic Body Radiotherapy in Patients With Locally Advanced Pancreatic Adenocarcinoma), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Phase 2 Study of mFOLFIRINOX With or Without Stereotactic Body Radiotherapy in Patients With Locally Advanced Pancreatic Adenocarcinoma
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundProspective data on stereotactic body radiation therapy (SBRT) combined with modified 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX) in patients with locally advanced unresectable pancreatic adenocarcinoma (PDAC) are limited. PATIENTS AND
methodsThe SABER trial was an open-label, randomized, phase 2 study. Patients with locally advanced, unresectable PDAC were eligible if they were suitable for SBRT with adherence to organ-at-risk constraints. Participants were randomized (1:1) to receive mFOLFIRINOX with or without SBRT. SBRT (35 Gy in five fractions) was administered within the first four cycles of mFOLFIRINOX. The primary endpoint was 1-year progression-free survival (PFS) rate.
resultsBetween September 2021 and January 2024, 37 out of a planned 92 patients were enrolled (18 in the mFOLFIRINOX+SBRT group; 19 in the mFOLFIRINOX group); the study was terminated early due to slow accrual. SBRT was delivered to 17 (94.4%) of 18 patients. After a median follow-up of 33.3 months (90% confidence interval [CI], 28.7-40.3), median PFS was 14.0 months with mFOLFIRINOX + SBRT and 11.7 months with mFOLFIRINOX alone (hazard ratio [HR] 0.66; 90% CI 0.35-1.25; p = 0.281); 1-year PFS was 66.7% versus 45.1%, respectively. Median OS was 28.9 versus 28.1 months (HR 0.80; 90% CI 0.38-1.68; p = 0.619), respectively. The rates of 1-year cumulative local and distant progression were 11.1% versus 39.1% (p = 0.096) and 22.2% versus 27.4% (p = 0.596), respectively. Safety profiles were comparable.
conclusionsAdditional SBRT to mFOLFIRINOX was feasible without safety concerns. Although it did not improve median PFS or OS, it led to numerically improved 1-year PFS rates and local tumor control. Given premature trial closure and limited power, efficacy comparisons should be interpreted as hypothesis generating.
trial registrationNCT04986930.
Indexed as
Identifiers
42098550What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.